Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines after FDA Approval

September 21, 2017

(Reuters) – In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market. A new analysis in the New England Journal of Medicine concludes that, in many cases, that’s not being done.